RecruitingPhase 2NCT06918834
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Studying Myelodysplastic neoplasm with low blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Intervention
- Immediate HSCT Group(other)
- Enrollment
- 236 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (5)
- Peking University People's Hospital, Beijin, Beijing Municipality, China
- Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China
- The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Jinan, Shandong, China
- People's Liberation Army The General Hospital of Western Theater Command, Chengdu, Sichuan, China
- The Second Hospital of Hebei Medical University, Shijia Zhuang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06918834 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with low blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07328191Quality of Life-Guided Transfusion in Refractory MDS or AMLCentre Hospitalier Universitaire de Nice
- RECRUITINGNCT07019155Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition VariantsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT06144515Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic SyndromeMinovia Therapeutics Ltd.
- RECRUITINGPHASE2NCT05924100Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDAssociazione Qol-one
- RECRUITINGPHASE1NCT05473910A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem TransplantationTScan Therapeutics, Inc.
- RECRUITINGNCT02269592Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeDana-Farber Cancer Institute
See all trials for Myelodysplastic neoplasm with low blasts →